Pharmacy Prior Authorization Criteria

Encelto (revakinagene taroretcel-lwey)

Indications for Prior Authorization

Encelto (revakinagene taroretcel-lwey)

• For diagnosis of Macular telangiectasia type 2 (MacTel)
  Indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).

Criteria

Encelto

Prior Authorization

Length of Approval: 1 Time Authorization per Eye in Lifetime

• Diagnosis of macular telangiectasia type 2 (MacTel)
AND
• Provider attests patient has not received prior treatment with Encelto in the affected eye in their lifetime
AND
• Prescribed by or in consultation with an ophthalmologist experienced in the treatment of retinal diseases

P & T Revisions

1970-01-01

References

1. Encelto Prescribing information. Neurotech Pharmaceuticals, Inc. Cumberland, RI. March 2025.

---

Revision History

---